Latest News

A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers

Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor

Two studies provide new insights on the effects of vaginal oestrogen therapy and physical exercise to tackle sexual impairment

In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment

No difference in risk recurrence or pregnancy outcomes was reported between young women with BRCA1 or BRCA2 mutations conceiving naturally and those using fertility treatments

However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it 

The rapidly increasing integration of AI into many aspects of breast cancer management calls for urgent definition of expected levels of evidence and bespoke regulatory and reimbursement processes

A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care 

A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib 

Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery